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Abstract
Purpose This study aims to determine the incidence of nausea
and vomiting (CINV) after moderately emetogenic chemo-
therapy (MEC), under medical practice conditions and the
accuracy with which physicians perceive CINV.
Methods Chemotherapy-naive patients receiving MEC be-
tween April 2012 andMay 2013 were included. Patients com-
pleted a diary of the intensity of nausea and number of
vomiting episodes. Complete response and complete protec-
tion were assessed as secondary endpoints.
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Results Of 261 patients included, 240 were evaluated.Median
age was 64 years, 44.2 % were female and 11.2 % were aged
less than 50 years; 95.3 % of patients received a combination
of 5-hydroxytryptamine 3 (5-HT3) antagonist+corticosteroid
as antiemetic treatment. Vomiting within 5 days of chemother-
apy administration occurred in 20.8 %, nausea in 42 % and
significant nausea in 23.8 % of patients. An increase in the
percentage of patients with significant nausea (from 9.4 to
21.7%) and vomiting (from 9.2 to 16.5%) was observed from
the acute to the delayed phase. Complete response was 84.2%
in the acute phase, 77% in the late phase and 68.9% in overall
period. Complete protection was 79.5 % in the acute phase,
68.8 % in the late phase and 62.4 % throughout the study
period. Physicians estimated prophylaxis would be effective
for 75 % of patients receiving MEC, compared with 54.1 %
obtained from patients’ diary.
Conclusion Despite receiving prophylactic treatment, 31% of
patients did not achieve a complete response and 38 % com-
plete protection. In general, nausea was worse controlled than
vomiting. The results also showed the late phase was worse
controlled than the acute phase in all variables. Healthcare
providers overestimated the effectiveness of antiemetic
prophylaxis.
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) is one
of the most common and most feared adverse events that can
be experienced by cancer patients [1–4]. CINV is associated
with significant morbidity which has a negative effect on pa-
tient quality of life. Its occurrence essentially depends on the
dose and type of chemotherapy agent used in treatment [5, 6].
There are currently many anti-emetic agents that may be
used as prophylaxis and treatment for CINV, including 5-
hydroxytryptamine 3 (5-HT3) receptor antagonists, corticoste-
roids, neurokinin 1 (NK-1) receptor antagonists, dopaminer-
gic receptor antagonists, benzodiazepines, neuroleptics and
cannabinoids [7]. However, despite the fact that antiemetic
treatments have been improving over the years with the intro-
duction of new drugs, there are still patients who are not
protected against CINV [8, 9]. Nausea and delayed CINV
(occurring >24 h post-chemotherapy) are reported as particu-
lar challenges in clinical practice [10–13].
Most studies that assess the incidence of chemotherapy-
induced nausea and vomiting have been conducted in groups
of patients who received highly emetogenic chemotherapy
(HEC). There are very few studies conducted with moderately
emetogenic chemotherapy (MEC), and these are mainly
limited to anthracycline-cyclophosphamide (AC) treatments
[13] which, nowadays, the majority of therapeutic guides con-
sider to be HEC [5, 6]. For this reason, there is very little data
related to the incidence of CINV in treatment-naive patients
who receive MEC and collected systematically as for example
by using a patient diary [14]. However, in studies that include
nausea and vomiting as an objective, it is recommended that
the information provided by the patients themselves is used, as
this will allow for a greater ability to compare the regimens
and data from various trials [4, 15]. Despite being able to
accurately predict the prevalence of acute CINV, health pro-
fessionals often underestimate the frequency of delayed nau-
sea and vomiting, so closer monitoring is required by them
throughout the complete treatment period [16].
There are hardly any studies in the medical literature with
MEC regimen containing carboplatin and other regimens used
in the treatment of colorectal cancer. The objective of this
study was to determine the incidence of nausea and vomiting
when appropriate antiemetic therapy is administered within
various MEC regimens, ensuring that these regimens
(carboplatin and oxaliplatin and/or irinotecan) were represent-
ed in the total sample, as well as to evaluate the perception




A prospective, observational multi-centre study conducted in
19 hospitals in Spain, between April 2012 and May 2013, in
patients diagnosed with cancer who were chemotherapy-naive
and who were scheduled to receive moderately emetogenic
chemotherapy treatment (MEC). In order to be included in
the study, patients had to have signed the informed consent
form, be adults (≥18 years old) and be indicated for treatment
with oxaliplatin and/or irinotecan in the case of colorectal
cancer and with carboplatin or MEC regimens (no AC) in
the case of any other type of cancer. Patients, who were unable
to take oral medication, presented vomiting in the 24 h pre-
ceding the first chemotherapy cycle were under treatment with
radiotherapy or presented with brain metastases were exclud-
ed from the study.
The allocation of a patient to a specific therapeutic strategy
was not previously decided by the protocol but rather was
determined by usual medical practice, and the decision to
prescribe chemotherapy treatment was prior to patient
inclusion.
The study was approved by the ethics committees at each
of the participating sites and was conducted in accordance
with Good Clinical Practice (GCP) guidelines and the Decla-
ration of Helsinki. All of the patients signed the informed
consent.
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Data collection and assessments
Investigators were instructed regarding the data to be recorded
during the study. Before administering the MEC to patients,
they had to answer three questions regarding their perception
of the incidence of nausea and vomiting following chemother-
apy administration, the use of rescue medication and their per-
ception of the efficacy of the antiemetic measures prescribed.
Patients’ demographic data, clinical information on the
cancer, metastases, chemotherapy regimen, administered pro-
phylaxis for vomiting and/or nausea and antiemetic medica-
tion prescribed were recorded by the investigator during the
course of the study. The study endpoints were complete re-
sponse defined as no emesis and no use of rescue therapy for
cycle 1 and complete protection defined as no emesis, no
significant nausea and no use of rescue medication. Signifi-
cant nausea was defined as nausea scored ≥25 mm to 100 mm
visual analogue scale (VAS).
The patients who agreed to participate in the study received
a diary covering the first 5 days following MEC administra-
tion. Patients were instructed on how to complete the diary, in
which they had to record the following on a daily basis:
vomiting and nausea episodes, the intensity of the nausea,
determined through a horizontal 100 mm VAS of which the
left end corresponded to BI have NO nausea today^ and the
right end to Bthe worst possible nausea^, as well as the use of
antiemetic rescue medication. On the first day of the second
cycle, they had to return the duly completed patient diary to
the doctor.
Sample size
A maximum of approximately 285 subjects were recruited.
According to previous estimates of the percentage of pa-
tients with MEC who experience an episode of vomiting and
assuming an accuracy of 10 %, 93 patients were needed to
detect an incidence of vomiting of 40 %, with an overall sig-
nificance of 0.05. Considering a 10 % of lost to follow up, the
number of patients were 102 per group. Groups 2 and 3 in-
cluded 90 patients each, and the analysis of these subgroups
included also to patients in the overall MEC group meet the
specific characteristics (or carboplatin-based regimens or pa-
tients diagnosed with CRC receiving oxaliplatin and/or
irinotecan), a final sample of 102 patients in each group are
guaranteed.
In the first phase, each site recruited seven patients treated
with MEC regimens and then, other six patients subsequently
were enrolled in each defined subgroup.
Statistical analysis
A descriptive analysis was performed on all of the variables
(demographic variables and characteristics of the patients, the
disease and the MEC treatment received) for all valid patients.
Quantitative variables were described through their mean, me-
dian, standard deviation, minimum, maximum and the total
number of patients with available data, and the qualitative
variables were in the form of tables with relative and absolute
frequencies. For the primary objective, the incidence of nau-
sea and vomiting associated with MEC regimens was evalu-
ated during the 5 days following administration, within the
first 24 h following administration of the first chemotherapy
cycle (acute phase) and during the four subsequent days (de-
layed phase), expressed using the percentage of patients with
vomiting and the percentage of patients with nausea and their
corresponding 95 % confidence intervals. For the secondary
objectives, the percentage of patients with vomiting, nausea,
significant nausea, use of rescue medication, lack of complete
response and lack of complete protection were analysed for
both acute and delayed phases of emesis.
The analyses performed with categorical result variables
used the chi-square test or Fisher’s exact test. McNemar’s test
was used for comparisons made between the two study phases
(acute and delayed). The Cochran-Armitage trend test was
used to evaluate a trend. The significance level used was




A total of 261 patients who receivedMECwere included in 16
hospitals between April 2012 and May 2013. Twenty-one of
themwere excluded from themain analysis due to not meeting
one or more of the inclusion/exclusion criteria. Of the 240
patients analysed, 44.2%were women and 11.2 %were under
the age of 50, with the mean age of the population being 64.
The patients’ characteristics are shown in Table 1.
Colorectal cancer was the most common type of cancer,
affecting 47.5 % of patients, followed by a lower incidence
of lung cancer and ovarian cancer. The most frequent chemo-
therapy combinations were oxaliplatin+capecitabine in 25 %
of cases and carboplatin+paclitaxel in 22.8 %. The antiemetic
treatment of choice in 95.3 % of the patients was a 5-HT3
antagonist+corticosteroid (±another drug). If this is broken
down by phase, in the acute phase, the most common prophy-
lactic treatment was the combination of setron+corticosteroid
in 94.9 % followed by metoclopramide+corticosteroid in
4.7 % of patients and one patient did not receive prophylaxis;
and in the delayed phase, the distribution was 56.2 % did not
receive prophylaxis in this phase, the most used prophylactic
treatment was metoclopramide+corticosteroid in 25.5 %
followed by setron+corticosteroid in 17 % and setron alone
in 1.3 % of patients.
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Incidence of chemotherapy-induced nausea and vomiting
(CINV)
Despite the use of antiemetic prophylaxis, a total of 103 pa-
tients (44.6 %) presented with nausea and/or vomiting at some
point during the 120 h following administration of chemother-
apy. Approximately 20.8 % experienced at least one episode
of vomiting, 42 % nausea of any intensity and significant
nausea in 23.8 % of patients.
In relation to CINV, no significant differences were found
with risk factors, age, sex and alcohol consumption except for
history of kinetosis (p=0.0281; chi-quare test).
Both the incidence of nausea and vomiting were much more
frequent in the delayed phase than during the acute phase. This
increase was statistically significant for all categories (vomiting,
nausea and significant nausea) and increased from 9.2 to 16.5 %
(p=0.0112; McNemar’s test), from 23.3 to 38.5 % (p<0.0001;
McNemar’s test) and from 9.4 to 21.7 % (p=0.0002;
McNemar’s test), respectively. These data are shown in Fig. 1.
The analysis by treatment group did not show significant differ-
ences between the different chemotherapy regimens adminis-
tered (Table 2). Particularly, the overall incidence of nausea
and vomiting in patients received XELOX regimens and pa-
tients received other regimens did not reach statistical signifi-
cance (42.9 vs. 45.3 %; p=0.7270; chi-square test).
Complete response and complete protection
Approximately three out of every ten patients (31.1 %) did not
achieve a complete response, and four out of every ten patients
(37.6 %) did not reach complete protection in spite of the
prophylactic treatment administered (Fig. 2). As it can be seen
in Table 3, the lack of complete response was higher during
the delayed phase than that observed in the acute phase (23 vs.
15.8%) and a similar situation was observed on evaluating the
complete protection of the patients; 31.2 % presented a lack of
complete protection in the delayed phase compared to 20.5 %
of patients in the acute phase.
Of the total number of patients, 17.9 % required rescue
medication compared to 82.1 % who did not need it. Approx-
imately 7.2 % of patients required it during the acute phase and
double this number (14.5%) in the delayed phase. By treatment
group, the frequency of use of rescue medication was lower in
the patients who received oxaliplatin and/or irinotecan, al-
though the differences were not statistically significant. The
rescue medication prescribed was metoclopramide in 26.4 %
of patients and ondansetron in 12.3 %.
Only 22 of the 229 patients who received a second MEC
cycle had their antiemetic treatment changed. Ten of these
patients had a lack of complete response or complete protec-
tion with the prophylaxis administered in the first cycle.
Physicians’ perception
Figure 3 shows the differences observed between the inci-
dence of CINV predicted by the investigators and that ob-
served in the study. According to the investigators, the expect-
ed percentage of patients with nausea and/or vomiting was
10 % lower than the data observed in the study (35 vs.
45 %) and, in addition, they believed that the prophylaxis
Table 1 Patient characteristics
Patient characteristics Percent No. patients
Age (M±SD) 64.4±10.6
Risk factors (n=238) 62.2 148
Age <50 years 11.2 27
Female 44.2 106
Background of motion sickness (n=239) 5.4 13
Moderate alcohol consumption (n=237) 21.9 52
Primary tumour
Colorectal cancer 47.5 114
Lung cancer 17.9 43
Ovary cancer 12.1 29
Endometrium cancer 5.4 13
Bladder cancer 5.0 12
Stomach/gastric cancer 3.3 8
Breast cancer 1.7 4










Oxaliplatin+5FU+calcium folinate 15.4 37
Other regimen 37.5 90
Antiemetic medication (n=235)
Acute phase
5-HT3 antagonist+corticoid 94.9 223
Metoclopramide+corticoid 4.7 11
No prophylaxis 0.4 1
Delayed phase
5-HT3 antagonist+corticoid 17.0 40
Metoclopramide+corticoid 25.5 60
5-HT3 antagonist 1.3 3
No prophylaxis 56.2 132
Rescue medication (n=235) 37.0 87
Metoclopramide 26.4 62
Ondansetron 12.3 29
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antiemetic treatment would be effective (no nausea, no
vomiting and no use of rescue medication) for 75 % of the
patients who received MEC, while the actual rate observed in
the study was for 54 %, which means a difference of 21 per-
centage points between the efficacy predicted by the investi-
gators and reality. On the other hand, the prediction by inves-
tigators of rescue medication use and that actually used in the
study was quite accurate.
Discussion
Chemotherapy-induced nausea and vomiting are a serious
problem for cancer patients and have a great impact on their
quality of life. Although preventive guidelines and the
development of new antiemetic agents have considerably re-
duced the incidence of CINV, between 13 and 32% of patients
who receive HEC or MEC chemotherapy experience
vomiting or the need for rescue medication during the acute
phase and more than 35 % present with nausea. However, the
incidence of CINV in the delayed phase increases up to 52 %
for nausea and 28 % for vomiting [16, 17] in patients treated
with MEC and antiemetic prophylaxis in regular medical
practice.
Our study is the only multi-centre study that has deter-
mined the incidence of CINV in Spain under routine clinical
practice conditions. The results indicate a rate of 42 % for
nausea and 21 % for vomiting in the first 5 days following
chemotherapy administration. The differences observed be-
tween the acute and the delayed phases concur with data from
other studies [16, 18, 19]. Approximately 9.2 % of patients
experienced vomiting in the acute phase of the first cycle and
16.4 % in the delayed phase, with the incidence of nausea
being higher, 23.3 and 38.5 %, respectively, in the two phases.
This indicates that there is poorer control of chemotherapy
effects in the days following administration. Similar results
have recently been published with regard to the Asian popu-
lation in patients treated with MEC regimens [20], and these
also highlight poorer control of CINV in the delayed phase
compared to the acute phase for the entire population. There
were no significant differences between the populations in the
various countries in the study during the acute phase, but there
were in the data for the delayed phase.
Fig. 1 Incidence CINV
Fig. 2 Patients with complete response and complete protection
Table 2 CINV per chemotherapy and phase
CINV Overall Carboplatin CRC (oxa/iri)
Total period n=231 n=99 n=110
Vomiting 48 (20.8) 22 (22.2) 19 (17.3)
Nausea 97 (42.0) 47 (47.5) 41 (37.3)
Significant nausea 55 (23.8) 25 (25.3) 25 (22.7)
No CINV 128 (55.4) 51 (52.5) 66 (60.0)
CINV 103 (44.6) 48 (48.5) 44 (40.0)
Acute Phase n=180 n=81 n=83
Vomiting 17 (9.2) 11 (13.6) 3 (3.6)
Nausea 42 (23.3) 21 (25.9) 18 (21.7)
Significant nausea 17 (9.4) 7 (8.6) 9 (10.8)
No CINV 137 (76.1) 59 (72.8) 65 (78.3)
CINV 43 (23.9) 22 (27.2) 18 (21.7)
Delayed phase n=231 n=99 n=110
Vomiting 38 (16.5) 15 (15.2) 17 (15.5)
Nausea 89 (38.5) 44 (44.4) 38 (34.5)
Significant nausea 50 (21.6) 22 (22.2) 23 (20.9)
No CINV 136 (58.9) 54 (54.5) 69 (62.7)
CINV 95 (41.1) 45 (45.5) 41 (37.3)
Nausea: VAS>5 mm; significant nausea: 25 mm<VAS<100 mm; acute
phase: first 24 h after MEC treatment; delayed phase: after first 24 h after
MEC treatment
CINV chemotherapy-induced nausea and vomiting
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The objective of antiemetic treatment should be complete
prevention of chemotherapy-induced nausea and vomiting for
the majority of patients who receive chemotherapy treatment.
The frequency of nausea and vomiting depends primarily on
the chemotherapy agent used, in addition to other factors such
as age, gender, alcohol consumption and history of kinetosis
(Figure S1). In our study, a significant upward trend was ob-
served between the number of factors present and a greater
incidence of CINV. However, unlike in other studies [13], no
significant association was found with any of the factors
alone, except for history of kinetosis.
Nevertheless, the poor control of nausea and vomiting in
the acute phase turned out to be an important risk factor for the
lack of control of these events in the delayed phase [21]. These
symptoms may appear, however, without acute nausea or
emesis [16]. In addition, the patients who presented with de-
layed nausea and vomiting in the first cycle of chemotherapy
have a greater risk of presenting with these symptoms in sub-
sequent cycles [22]; therefore, good control of nausea and
vomiting in the first cycle is necessary in order to control them
well in subsequent chemotherapy cycles.
It is remarkable how, despite having the improved preven-
tion and control of acute emesis, the same has not occurred in
the delayed phase, and this continues to be a significant prob-
lem in patients who receive chemotherapy, particularly in
terms of nausea.
Current guidelines [23, 24] recommend that management
of CINV should be based primarily on the emetogenic poten-
tial of the drugs selected for chemotherapy, which have been
classified into four emetogenic risk groups: high, moderate,
low and minimal. Nowadays, for patients who receive regi-
mens with a high emetogenic potential, the combination of 5-
HT3 receptor antagonist, aprepitant and dexamethasone is rec-
ommended before chemotherapy, while in regimens with
moderate emetogenic potential, the guidelines establishes the
use of palonosetron+dexamethasone, but the key question is
whether aprepitant should be part of antiemetic prophylaxis as
a third agent [25]. In this context, all guindelines (ASCO;
Table 3 Absence complete
response and complete protection
per chemotherapy and phase
Overall (%) Carboplatin (%) CRC (oxa/iri) (%)
Total period
Absence complete response 31.1 34.2 23.5
Absence complete protection 37.6 39.2 32.9
Acute phase
Absence complete response 15.8 23.5 6.0
Absence complete protection 20.5 25.9 13.1
Delayed phase
Absence complete response 23.0 23.5 19.1
Absence complete protection 31.2 34.3 26.4
Absence complete response: with emesis or use of rescue medication; Absence complete protection: emesis or
significant nausea or use of rescue medication
Fig. 3 Physicians’ perception vs.
study results
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MASCC/ESMO and NCCN) suggest that the triple combina-
tion (aprepitant, 5-HT3 receptor antagonist and dexamethasone)
should be used only in patients who receive AC regimens [9].
Antiemetic medication is also recommended in the days
following chemotherapy in order to prevent delayed vomiting
and nausea [25]. The adherence to the guidelines and its appli-
cation in the management of patients treated with chemothera-
py regimens with high and moderate emetogenic potential en-
ables the incidence of CINV to be reduced and may mean that
10 % more patients achieve a complete response [22]. Howev-
er, compliance with these guidelines appears to be very low and
the prescription of antiemetics to patients with HEC or MEC
regimens is often inadequate. There is a good deal of variation
with regard to doses administered and suboptimal control of
CINV [8, 26], particularly in the days following the chemother-
apy when patients are at home and not under the direct super-
vision of clinic staff [26, 27]. This observation is in line with
those made by Doranne [13]; while the patients who developed
CINVon the day of their treatment were likely to receive addi-
tional antiemetic treatment, the symptoms they developed after
2 to 5 days did not affect CINV management, as demonstrated
by the data from the study.
In our study, the prophylaxis treatment of choice in 95.3 %
of the patients was 5-HT3+corticosteroid, and rescue medica-
tion was prescribed to 37% of patients. In spite of this, 31.1 %
of patients did not achieve complete response and 37.6 %
presented with vomiting or significant nausea or required res-
cue medication, this being more significant in the delayed
phase than in the acute phase. As shown in our results, pro-
phylactic antiemetic treatment always included an corticoste-
roid, both in the acute phase and the late phase, evidencing the
importance of adherence to corticosteroids for the enhancing
the antiemetic effect of metoclopramide and 5-HT3
antagonists.
However, our results confirm that physicians’ perception of
the incidence of CINV in MEC regimens is not in line with
reality [28], since they underestimate said rate [16, 29]. In our
case, investigators underestimated the incidence of nausea and
vomiting for the overall population and regimens with
carboplatin. However, they overestimated CINV in patients
with colorectal cancer who received oxaliplatin and/or
irinotecan regimens, and the efficacy of the antiemetic treat-
ment. A total of 52 % of patients did not make use of the
rescue medication prescribed. The underestimation of the in-
cidence of delayed CINV leads to undertreatment of delayed
emesis. It seems clear that despite the existence of guidelines
and protocols for treatment and follow-up of patients receiv-
ingMEC, the adherence to them in the clinical practice is very
low. Communication between professional and patients about
this side effect may help improve outcomes. Addressing mis-
conceptions and establishing mutually consistent goals will
lead to more effective overall care. It is necessary to establish
and to improve efficient education and training of clinicians/
nurses. The use of standardized protocols that include chemo-
therapy antiemetic treatment required according to the
emetogenic risk, as well as the monitoring of patients receiv-
ing MEC by use of Bpatient diary .^
The primary limitations of this study, on one hand, consist
of the consequences of its observational design and the lack of
follow-up until several cycles had been completed. And on the
other, we cannot rule out errors or omissions made when pa-
tients completed the diary.
In conclusion, the results of this study reveal that the pa-
tients who receive moderately emetogenic chemotherapy con-
tinue to experience nausea and vomiting despite the antiemetic
treatment administered. Furthermore, the advances achieved
in controlling vomiting in the acute phase do not correspond to
better control in the delayed phase, where nausea is still not
effectively controlled.
Finally, we believe it is necessary to implement actions that
ensure the knowledge and application of the antiemetic guide-
lines or recommendations agreed upon by various expert or-
ganisations when establishing prophylactic antiemetic mea-
sures and to show that, in the majority of cases, physicians
underestimate the incidence of nausea and vomiting in pa-
tients receiving MEC.
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